Your Good Partner in Biology Research

  1. 首頁
  2. 蛋白
  3. 重組蛋白
  4. Recombinant Human GTPase HRas (HRAS)

Recombinant Human GTPase HRas (HRAS)

  • 中文名稱：
    人HRAS重組蛋白
  • 貨號：
    CSB-YP010726HU
  • 規(guī)格：
  • 來源：
    Yeast
  • 其他：
  • 中文名稱：
    人HRAS重組蛋白
  • 貨號：
    CSB-EP010726HU
  • 規(guī)格：
  • 來源：
    E.coli
  • 其他：
  • 中文名稱：
    人HRAS重組蛋白
  • 貨號：
    CSB-EP010726HU-B
  • 規(guī)格：
  • 來源：
    E.coli
  • 共軛：
    Avi-tag Biotinylated

    E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.

  • 其他：
  • 中文名稱：
    人HRAS重組蛋白
  • 貨號：
    CSB-BP010726HU
  • 規(guī)格：
  • 來源：
    Baculovirus
  • 其他：
  • 中文名稱：
    人HRAS重組蛋白
  • 貨號：
    CSB-MP010726HU
  • 規(guī)格：
  • 來源：
    Mammalian cell
  • 其他：

產(chǎn)品詳情

  • 純度：
    >85% (SDS-PAGE)
  • 基因名：
  • Uniprot No.：
  • 別名：
    C BAS/HAS; C HA RAS1; C-BAS/HAS; c-H-ras; C-HA-RAS1; CTLO; GTPase HRas; GTPase KRas; GTPase NRas; H ras; H RASIDX; H-Ras-1; H-RASIDX; Ha-Ras; HAMSV; HRAS; HRAS1; K ras; K RAS2A; K RAS2B; K RAS4A; K RAS4B; K-RAS; KRAS; KRAS1; KRAS2; N-RAS; N-terminally processed; NRAS; NRAS1; p21ras; RASH_HUMAN; RASH1; RASK2; Transforming protein p21; v Ha ras Harvey rat sarcoma viral oncogene homolog; v Ki ras2 Kirsten rat sarcoma viral oncogene homolog; v ras neuroblastoma RAS viral oncogene homolog
  • 種屬：
    Homo sapiens (Human)
  • 蛋白長度：
    Full length protein
  • 表達區(qū)域：
    1-186
  • 氨基酸序列
    MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHQYREQI KRVKDSDDVP MVLVGNKCDL AARTVESRQA QDLARSYGIP YIETSAKTRQ GVEDAFYTLV REIRQHKLRK LNPPDESGPG CMSCKC
  • 蛋白標簽：
    Tag?type?will?be?determined?during?the?manufacturing?process.
    The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
  • 產(chǎn)品提供形式：
    Lyophilized powder
    Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
  • 復溶：
    We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
  • 儲存條件：
    Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
  • 保質(zhì)期：
    The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
    Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
  • 貨期：
    Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
    Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
  • 注意事項：
    Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
  • Datasheet ：
    Please contact us to get it.

產(chǎn)品評價

靶點詳情

  • 功能：
    Involved in the activation of Ras protein signal transduction. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • 基因功能參考文獻：
    1. results demonstrate that adenomyoepitheliomas are genetically heterogeneous, and qualify mutations in HRAS, a gene whose mutations are vanishingly rare in common-type breast cancers, as likely drivers of ER-negative adenomyoepitheliomas PMID: 29739933
    2. Plasma membrane polyphosphoinositides depletion caused rapid translocation of K-Ras4B but not H-Ras from the plasma membrane to the Golgi. PMID: 28939768
    3. Data show that an indispensable beta-subunit of the voltage-gated Ca(2+) channel Cav1.2 interaction with H-Ras is independently of Ca(2+) flux, suggesting the regulatory role of beta2 in transcriptional activation via the ERK/CREB pathway. PMID: 30150369
    4. This study demonstrated that Oligodendrocyte RasG12V expressed in its endogenous locus disrupts myelin structure through increased MAPK, nitric oxide, and notch signaling. PMID: 28856719
    5. Data indicate dynamic of H-Ras functional cycle as controlled by son of sevenless homolog 1 (Sos). PMID: 27412770
    6. Our data support the idea that a variable range of dysregulated HRAS-dependent signalling dynamics, rather than static activation of HRAS-dependent signal flow, may underlie the phenotypic variability in CS. PMID: 28139825
    7. AF6 employs a non-canonical, evolutionarily conserved alpha-helix to bind RAS, unique to AF6 and the classical RASSF effectors. PMID: 29062045
    8. Case Report: somatic HRAS mutation in pigmented trichoblastoma developed in a sebaceous nevus. PMID: 28554764
    9. our identification of the novel interaction between Aurora A and H-Ras as a mechanism by which Aurora A can activate Ras-MAPK signaling opens the way for studies into perturbation of the Aurora A/H-Ras interaction and the effect on Ras-MAPK signaling. PMID: 28177880
    10. Peroxiredoxin I (Prx I) increased in tumors of hepatocellular carcinoma (HCC) patients that aligned with overexpression of oncogenic H-ras. PMID: 27517622
    11. Familial alcohol dependence was associated with hypomethylation of CpG sites in the HRAS promoter region. PMID: 28799801
    12. Suppression of MEK/ERK pathway in senescent cells provides a new strategy for elimination of Ras-expressing cells. PMID: 29140794
    13. ESR1 inhibits senescence-like phenotype and facilitates transformation induced by oncogenic ras in human mammary epithelial cells PMID: 27259243
    14. Data show that STK38 supports Ras-driven transformation through promoting detachment-induced autophagy. PMID: 27283898
    15. Data indicate acquired KRAS, NRAS or HRAS mutations in more than one third of patients after cetuximab exposure. PMID: 27119512
    16. HRAS mutations were more common in epithelial-myoepithelial carcinomas (EMCAs) with intact PLAG1 and HMGA2. Most EMCAs arose ex pleomorphic adenoma (PA)and the genetic profile of EMCA varies with the absence or presence of preexisting PA and its cytogenetic signature. Progression to higher grade EMCA with intact PLAG1 and HMGA2 correlates with the presence of TP53, FBXW7 mutations, or SMARCB1 deletion. PMID: 29135520
    17. Analysis of HRAS mutations and their respiratory phenotype revealed that the common p.Gly12Ser mutation is more often associated with transient respiratory distress and other respiratory diagnoses. PMID: 27102959
    18. we found that H-Ras proteins and particularly the G12V and G13D variants are significantly more flexible than their K-Ras counterparts.while most of the simulated proteins sampled the effector-interacting state 2 conformational state, G12V and G13D H-Ras adopted an open switch state 1 conformation that is defective in effector interaction PMID: 28498561
    19. The HRAS mutation p.T58I could manifest with severe early-onset but stabilizing cardiomyopathy. The dysmorphic features are mild compared with the features of Costello syndrome. The phenotypic variability makes the diagnosis challenging, suggesting that this variant of Costello syndrome might go undiagnosed. PMID: 26888048
    20. Age at diagnosis of follicular thyroid cancer (FTC) and frequency of extrathyroidal extension have changed over four decades; prevalence of RAS mutations has decreased; HRAS/NRAS (codon 61) and TERT (promoter) mutations may be associated with poor clinical outcomes in FTC, especially when two mutations coexist; this retrospective study was conducted in Seoul. PMID: 28864536
    21. Knockdown of forkhead Box M1 (FoxM1) reduced Prx II levels in H-ras(G12V)-hepatocellular carcinoma (HCC) cells, indicating FoxM1 as a direct transcription factor of Prx II in HCC. PMID: 26500057
    22. we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CIB1 expression. We previously described the Ca(2+)-myristoyl switch function of CIB1, and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1), a location where SK1 is known to elicit oncogenic signalling. PMID: 27941888
    23. Data suggest that isoform-specific sequences in the allosteric lobes of HRAS, KRAS, and NRAS have an impact on biocatalysis (kinetics of GTP hydrolysis) and interaction with c-Raf kinase, which must be due to allosteric effects on dynamics and conformational states, given the identical active sites of these isoenzymes. PMID: 28630043
    24. Data suggest HRas activates both p110alpha and p110delta isoforms; membrane-resident HRas, not soluble HRas, increases membrane recruitment of both p110alpha and p110delta. (HRas = v-Ha-ras Harvey rat sarcoma viral oncogene homolog; p110alpha = class IA phosphoinositide 3-kinases, subunit p110alpha; p110delta = class IA phosphoinositide 3-kinases, subunit p110delta) PMID: 28515318
    25. Our data suggest that testing for any RAS mutation is unlikely to change the clinical management of thyroid nodules that have indeterminate cytology PMID: 28116986
    26. Equilibrium dissociation constants were determined for the binding of HRAS, KRAS, NRAS and RRAS2 to the RAS binding (RB) domain of binding proteins. PMID: 27936046
    27. Studies indicate that RAS proteins were among the first oncogenes identified and are mutationally activated in 30% of all cancer types. PMID: 28202657
    28. 6 of 7 (86%) malignant ectomesenchymomas had HRAS mutations PMID: 26872011
    29. RAS-positive thyroid cancer most often demonstrates indolent sonographic features and more commonly associates with lower risk, "indeterminate" cytology. PMID: 27689252
    30. Studies indicate that the control of spatiotemporal RAS protein signalling show that activation kinetics and subcellular compartmentalisation are tightly coupled to the generation of specific biological outcomes. PMID: 27911734
    31. HRAS mutation is associated in children with delayed puberty and probably with precocious puberty. PMID: 27940666
    32. HRAS mutation is associated with salivary duct carcinoma. PMID: 27379604
    33. Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes has been analyzed in a multi-cancer bioinformatics approach. PMID: 27074591
    34. Ras isoforms' dimer conformations are not uniform; instead, the isoform-specific dimers reflect the favoured interactions of the HVRs (hypervariable regions) with cell membrane microdomains, biasing the effector-binding site orientations, thus isoform binding selectivity. PMID: 27057007
    35. Two unrelated boys with Costello syndrome and an HRAS mutation (p.Gly13Cys) are presented with their ophthalmologic findings. Both had early symptoms of nystagmus, photophobia, and vision abnormalities PMID: 28337834
    36. The fact that no malignant tumors were described in these individuals does not allow definitive conclusions about the risk for cancer development. It remains to be determined if substitutions of amino acid 13 in HRAS (p.Gly13Asp and p.Gly13Cys) increase the risk of tumor development PMID: 28371260
    37. Overexpression of K-p21Ras was found in all colorectal cancer tissues tested, overexpression of N-p21Ras was found in 85.7% of the colorectal cancertissues, while H-p21Ras expression was not found in any colorectal cancer tissue. PMID: 28259994
    38. herefore, our results also demonstrate that the phenotype in CS and somatic cancers is not only determined by the different transforming potentials of mutant HRAS proteins, but also by the efficiency of exon 2 inclusion resulting from the different HRAS mutations. PMID: 27195699
    39. Point mutations of HRAS is associated with thyroid cancer. PMID: 27535135
    40. The results show that mutant RAS is associated with an earlier and higher rate of local tumour progression in patients undergoing ablation of CLMs. PMID: 28240361
    41. A report of three cases with pediatric urothelial bladder cancer indicates that the tumors are characterized by a consistent H-RAS mutation status, whereas FGFR3 and p53 pathways are not involved in this tumor initiation. PMID: 26522772
    42. The coexistence of BRAF or RAS mutations enhanced the prognostic effects of telomerase reverse transcriptase (TERT) promoter mutations. Furthermore, TERT promoter mutations strengthened the predictions of mortality and recurrence by the ATA and TNM staging systems, particularly for high-risk patients with differentiated thyroid cancer. PMID: 26969876
    43. Overexpression of HRAS is associated with Breast Cancer Recurrence. PMID: 27165221
    44. Study acts as a further supplement of the genetic features of neuroendocrine tumors. Somatic mutations of three potential tumor-related genes (HRAS, PAK1 and MEN1) might contribute to the tumorigenesis of thymic neuroendocrine tumors with EAS. PMID: 27913610
    45. Activating HRAS, KRAS and EGFR mutations play a major role in the pathogenesis of sporadic SGH. These results support the concept that SGH is a true benign neoplasm rather than a reactive hyperplasia. PMID: 26804118
    46. HRAS mutation is associated with liver cancer. PMID: 26799184
    47. findings support a role of HRAS mutations as a somatic driver event in benign PPGL without other known susceptibility gene mutations. HRAS mutated PPGL cluster together with NF1- and RET-mutated tumors associated with activation of kinase-signaling pathways PMID: 26773571
    48. Ras activity fine tunes the period length and modulates photoentrainment of the circadian clock. PMID: 25762011
    49. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells. PMID: 26636543
    50. Data show that Ba/F3 cells transformed with mutant HRAS protien indicated equal sensitivity towards Map kinase kinase (MEK) and mTOR serine-threonine kinase (mTOR) inhibition. PMID: 26544513

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Costello syndrome (CSTLO); Congenital myopathy with excess of muscle spindles (CMEMS); Thyroid cancer, non-medullary, 2 (NMTC2); Bladder cancer (BLC); Schimmelpenning-Feuerstein-Mims syndrome (SFM)
  • 亞細胞定位：
    Cell membrane; Lipid-anchor; Cytoplasmic side. Golgi apparatus. Golgi apparatus membrane; Lipid-anchor.; [Isoform 2]: Nucleus. Cytoplasm. Cytoplasm, perinuclear region. Note=Colocalizes with RACK1 to the perinuclear region.
  • 蛋白家族：
    Small GTPase superfamily, Ras family
  • 組織特異性：
    Widely expressed.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 5173

    OMIM: 109800

    KEGG: hsa:3265

    STRING: 9606.ENSP00000309845

    UniGene: Hs.37003